Cargando…

Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients

OBJECTIVES: Our objective was to determine the antibody and cytokine profiles in different COVID-19 patients. METHODS: COVID-19 patients with different clinical classifications were enrolled in this study. The level of IgG antibodies, IgA, IgM, IgE, and IgG subclasses targeting N and S proteins were...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yaolin, Li, Tianyi, Xia, Xinyi, Su, Bin, Li, Hanping, Feng, Yingmei, Han, Jingwan, Wang, Xiaolin, Jia, Lei, Bao, Zuoyi, Li, Jingyun, Liu, Yongjian, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417126/
https://www.ncbi.nlm.nih.gov/pubmed/34489974
http://dx.doi.org/10.3389/fimmu.2021.723585
_version_ 1783748322796765184
author Guo, Yaolin
Li, Tianyi
Xia, Xinyi
Su, Bin
Li, Hanping
Feng, Yingmei
Han, Jingwan
Wang, Xiaolin
Jia, Lei
Bao, Zuoyi
Li, Jingyun
Liu, Yongjian
Li, Lin
author_facet Guo, Yaolin
Li, Tianyi
Xia, Xinyi
Su, Bin
Li, Hanping
Feng, Yingmei
Han, Jingwan
Wang, Xiaolin
Jia, Lei
Bao, Zuoyi
Li, Jingyun
Liu, Yongjian
Li, Lin
author_sort Guo, Yaolin
collection PubMed
description OBJECTIVES: Our objective was to determine the antibody and cytokine profiles in different COVID-19 patients. METHODS: COVID-19 patients with different clinical classifications were enrolled in this study. The level of IgG antibodies, IgA, IgM, IgE, and IgG subclasses targeting N and S proteins were tested using ELISA. Neutralizing antibody titers were determined by using a toxin neutralization assay (TNA) with live SARS-CoV-2. The concentrations of 8 cytokines, including IL-2, IL-4, IL-6, IL-10, CCL2, CXCL10, IFN-γ, and TNF-α, were measured using the Protein Sample Ella-Simple ELISA system. The differences in antibodies and cytokines between severe and moderate patients were compared by t-tests or Mann-Whitney tests. RESULTS: A total of 79 COVID-19 patients, including 49 moderate patients and 30 severe patients, were enrolled. Compared with those in moderate patients, neutralizing antibody and IgG-S antibody titers in severe patients were significantly higher. The concentration of IgG-N antibody was significantly higher than that of IgG-S antibody in COVID-19 patients. There was a significant difference in the distribution of IgG subclass antibodies between moderate patients and severe patients. The positive ratio of anti-S protein IgG3 is significantly more than anti-N protein IgG3, while the anti-S protein IgG4 positive rate is significantly less than the anti-N protein IgG4 positive rate. IL-2 was lower in COVID-19 patients than in healthy individuals, while IL-4, IL-6, CCL2, IFN-γ, and TNF-α were higher in COVID-19 patients than in healthy individuals. IL-6 was significantly higher in severe patients than in moderate patients. The antibody level of anti-S protein was positively correlated with the titer of neutralizing antibody, but there was no relationship between cytokines and neutralizing antibody. CONCLUSIONS: Our findings show the severe COVID-19 patients’ antibody levels were stronger than those of moderate patients, and a cytokine storm is associated with COVID-19 severity. There was a difference in immunoglobulin type between anti-S protein antibodies and anti-N protein antibodies in COVID-19 patients. And clarified the value of the profile in critical prevention.
format Online
Article
Text
id pubmed-8417126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84171262021-09-05 Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients Guo, Yaolin Li, Tianyi Xia, Xinyi Su, Bin Li, Hanping Feng, Yingmei Han, Jingwan Wang, Xiaolin Jia, Lei Bao, Zuoyi Li, Jingyun Liu, Yongjian Li, Lin Front Immunol Immunology OBJECTIVES: Our objective was to determine the antibody and cytokine profiles in different COVID-19 patients. METHODS: COVID-19 patients with different clinical classifications were enrolled in this study. The level of IgG antibodies, IgA, IgM, IgE, and IgG subclasses targeting N and S proteins were tested using ELISA. Neutralizing antibody titers were determined by using a toxin neutralization assay (TNA) with live SARS-CoV-2. The concentrations of 8 cytokines, including IL-2, IL-4, IL-6, IL-10, CCL2, CXCL10, IFN-γ, and TNF-α, were measured using the Protein Sample Ella-Simple ELISA system. The differences in antibodies and cytokines between severe and moderate patients were compared by t-tests or Mann-Whitney tests. RESULTS: A total of 79 COVID-19 patients, including 49 moderate patients and 30 severe patients, were enrolled. Compared with those in moderate patients, neutralizing antibody and IgG-S antibody titers in severe patients were significantly higher. The concentration of IgG-N antibody was significantly higher than that of IgG-S antibody in COVID-19 patients. There was a significant difference in the distribution of IgG subclass antibodies between moderate patients and severe patients. The positive ratio of anti-S protein IgG3 is significantly more than anti-N protein IgG3, while the anti-S protein IgG4 positive rate is significantly less than the anti-N protein IgG4 positive rate. IL-2 was lower in COVID-19 patients than in healthy individuals, while IL-4, IL-6, CCL2, IFN-γ, and TNF-α were higher in COVID-19 patients than in healthy individuals. IL-6 was significantly higher in severe patients than in moderate patients. The antibody level of anti-S protein was positively correlated with the titer of neutralizing antibody, but there was no relationship between cytokines and neutralizing antibody. CONCLUSIONS: Our findings show the severe COVID-19 patients’ antibody levels were stronger than those of moderate patients, and a cytokine storm is associated with COVID-19 severity. There was a difference in immunoglobulin type between anti-S protein antibodies and anti-N protein antibodies in COVID-19 patients. And clarified the value of the profile in critical prevention. Frontiers Media S.A. 2021-08-19 /pmc/articles/PMC8417126/ /pubmed/34489974 http://dx.doi.org/10.3389/fimmu.2021.723585 Text en Copyright © 2021 Guo, Li, Xia, Su, Li, Feng, Han, Wang, Jia, Bao, Li, Liu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Guo, Yaolin
Li, Tianyi
Xia, Xinyi
Su, Bin
Li, Hanping
Feng, Yingmei
Han, Jingwan
Wang, Xiaolin
Jia, Lei
Bao, Zuoyi
Li, Jingyun
Liu, Yongjian
Li, Lin
Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients
title Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients
title_full Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients
title_fullStr Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients
title_full_unstemmed Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients
title_short Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients
title_sort different profiles of antibodies and cytokines were found between severe and moderate covid-19 patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417126/
https://www.ncbi.nlm.nih.gov/pubmed/34489974
http://dx.doi.org/10.3389/fimmu.2021.723585
work_keys_str_mv AT guoyaolin differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT litianyi differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT xiaxinyi differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT subin differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT lihanping differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT fengyingmei differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT hanjingwan differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT wangxiaolin differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT jialei differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT baozuoyi differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT lijingyun differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT liuyongjian differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients
AT lilin differentprofilesofantibodiesandcytokineswerefoundbetweensevereandmoderatecovid19patients